Pain paths among post-COVID-19 condition subjects: A prospective cross-sectional study with in-person evaluation

Nenhuma Miniatura disponível
Citações na Scopus
8
Tipo de produção
article
Data de publicação
2023
DOI
Scopus
Web of Science
PubMed
Título da Revista
ISSN da Revista
Título do Volume
Editora
WILEY
Autores
Citação
EUROPEAN JOURNAL OF PAIN, v.27, n.5, p.636-650, 2023
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
BackgroundNew-onset chronic pain has been acknowledged as part of the post-COVID-19 condition. However, available fine-grained data about its clinical phenotype, trajectories and main associated characteristics remain scarce. We described the distinct temporal evolutions of post-COVID-19 pain and their epidemiological and phenotypical features. MethodsA prospective cross-sectional study enrolled post-COVID-19 condition patients (i.e. who had persisting COVID-19-related symptoms over 30 days since their first positive laboratory test), whose COVID-19 diagnosis had been supported by RT-PCR of oral/nasopharyngeal swab or serology. They underwent in-person evaluations with a structured interview, pain and quality-of-life-related questionnaires and thorough physical examination. Chronic pain (CP) and probable neuropathic pain (NP) were defined according to IASP criteria. ResultsThe present study included 226 individuals, 177 (78.3%) of whom presented over 3 months since their first COVID-19 symptom. New-onset pain occurred in 170 (75.2%) participants and was chronic in 116 (68.2%). A chronic course was associated with COVID-19-related hospitalization, new-onset fatigue, lower cognitive performance, motor and thermal sensory deficits, mood and sleep impairments and overall lower quality-of-life levels. Probable NP occurred in only 7.6% new-onset pain patients, and was associated with pain chronification, new-onset fatigue, motor and thermal sensory deficits, mechanical allodynia and lower rates of SARS-CoV-2 vaccination. Previous CP was reported by 86 (38.1%) individuals and had aggravated after the infection in 66 (76.7%) of them, which was associated with orthostatic hypotension. ConclusionsPost-COVID pain phenomena follow different paths, which are associated with specific clinical and epidemiological features, and possibly distinct underlying mechanisms, prognostic and therapeutic implications. SignificanceCOVID-19-related pain usually follows a chronic course and is non-neuropathic. Its possible courses and phenotypes are associated with distinct clinical and epidemiological features. This suggests differing underlying mechanisms, which may have significant prognostic and therapeutic implications.
Palavras-chave
URI
https://observatorio.fm.usp.br/handle/OPI/53770
Referências
  1. Bakilan F, 2021, INT J CLIN PRACT, V75, DOI 10.1111/ijcp.14734
  2. Bauer L, 2022, TRENDS NEUROSCI, V45, P358, DOI 10.1016/j.tins.2022.02.006
  3. Bouhassira D, 2004, PAIN, V108, P248, DOI 10.1016/j.pain.2003.12.024
  4. Bouhassira D, 2021, PAIN, V162, P1038, DOI 10.1097/j.pain.0000000000002130
  5. Bulfamante G, 2021, J NEUROL, V268, P4486, DOI 10.1007/s00415-021-10604-8
  6. Caramelli P, 2007, ALZ DIS ASSOC DIS, V21, P65, DOI 10.1097/WAD.0b013e31802f244f
  7. Carvalho Guilherme Almeida, 2020, Dement. neuropsychol., V14, P14, DOI 10.1590/1980-57642020dn14-010003
  8. Center for Disease Control and Prevention, 2022, LONG COVID POSTCOVID
  9. de Andrade DC, 2011, HEALTH QUAL LIFE OUT, V9, DOI 10.1186/1477-7525-9-107
  10. Di Stefano G, 2023, EUR J PAIN, V27, P44, DOI 10.1002/ejp.2055
  11. Fernandez-de-las-Penas C, 2022, VIRUSES-BASEL, V14, DOI 10.3390/v14122629
  12. Fernandez-de-las-Penas C, 2023, PAIN, V164, P413, DOI 10.1097/j.pain.0000000000002718
  13. Fernandez-de-las-Penas C, 2022, PAIN, V163, P2112, DOI 10.1097/j.pain.0000000000002608
  14. Fernandez-de-las-Penas C, 2022, PAIN, V163, pE989, DOI 10.1097/j.pain.0000000000002564
  15. Fernandez-de-las-Penas C, 2022, PAIN, V163, P1220, DOI 10.1097/j.pain.0000000000002496
  16. Fernandez-de-las-Penas C, 2021, PAIN, V162, P2832, DOI 10.1097/j.pain.0000000000002306
  17. Ferreira KA, 2011, SUPPORT CARE CANCER, V19, P505, DOI 10.1007/s00520-010-0844-7
  18. Finnerup NB, 2016, PAIN, V157, P1599, DOI 10.1097/j.pain.0000000000000492
  19. Fiocruz, 2023, DASHB EN GEN
  20. Harris PA, 2019, J BIOMED INFORM, V95, DOI 10.1016/j.jbi.2019.103208
  21. Harris PA, 2009, J BIOMED INFORM, V42, P377, DOI 10.1016/j.jbi.2008.08.010
  22. Herrero-Montes M, 2022, INT J CLIN PRACT, V2022, DOI 10.1155/2022/3532917
  23. Jena D, 2022, AM J PHYS MED REHAB, V101, P411, DOI 10.1097/PHM.0000000000001969
  24. Karaarslan F, 2022, CLIN RHEUMATOL, V41, P289, DOI 10.1007/s10067-021-05942-x
  25. Kemp HI, 2020, BRIT J ANAESTH, V125, P436, DOI 10.1016/j.bja.2020.05.021
  26. Knox N, 2021, MAYO CLIN PROC, V96, P943, DOI 10.1016/j.mayocp.2020.12.014
  27. Kubota GT, 2022, EUR J PAIN, V26, P282, DOI 10.1002/ejp.1889
  28. Kurcaloglu M, 2021, AGRI, V33, P215, DOI 10.14744/agri.2021.92609
  29. Lee K, 2009, GLOB INST, P1
  30. Lopez-Leon S, 2021, SCI REP-UK, V11, DOI [10.1038/s41598-021-95565-8, 10.1101/2021.01.27.21250617]
  31. Magdy R, 2022, PAIN MED, V23, P774, DOI 10.1093/pm/pnab341
  32. Matschke J, 2020, LANCET NEUROL, V19, P919, DOI 10.1016/S1474-4422(20)30308-2
  33. Menezes RD, 2015, QUAL LIFE RES, V24, P2761, DOI 10.1007/s11136-015-0994-7
  34. Murat S, 2021, IRISH J MED SCI, V190, P913, DOI 10.1007/s11845-020-02433-x
  35. Nasserie T, 2021, JAMA NETW OPEN, V4, DOI 10.1001/jamanetworkopen.2021.11417
  36. Oguz-Akarsu E, 2022, EUR J PAIN, V26, P492, DOI 10.1002/ejp.1876
  37. Ojeda A, 2022, EUR J PAIN, V26, P680, DOI 10.1002/ejp.1897
  38. Ramakrishnan RK, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.686029
  39. Ronchini C, 2022, PLOS ONE, V17, DOI 10.1371/journal.pone.0263014
  40. Sahin T, 2021, AM J PHYS MED REHAB, V100, P307, DOI 10.1097/PHM.0000000000001699
  41. Santos JG, 2010, J PAIN, V11, P484, DOI 10.1016/j.jpain.2009.09.014
  42. Santos M, 2016, MED DECIS MAKING, V36, P253, DOI 10.1177/0272989X15613521
  43. Sarzi-Puttini P, 2020, NAT REV RHEUMATOL, V16, P645, DOI 10.1038/s41584-020-00506-w
  44. Schultheiss C, 2022, CELL REP MED, V3, DOI 10.1016/j.xcrm.2022.100663
  45. Soares FHC, 2021, EUR J PAIN, V25, P1342, DOI 10.1002/ejp.1755
  46. Solomon IH, 2020, NEW ENGL J MED, V383, P989, DOI 10.1056/NEJMc2019373
  47. Sorensen RJD, 2022, LANCET, V399, P1469, DOI 10.1016/S0140-6736(21)02867-1
  48. Soriano JB, 2022, LANCET INFECT DIS, V22, pE102, DOI 10.1016/S1473-3099(21)00703-9
  49. Taquet M, 2021, PLOS MED, V18, DOI 10.1371/journal.pmed.1003773
  50. Tenforde MW, 2021, JAMA-J AM MED ASSOC, V326, P2043, DOI 10.1001/jama.2021.19499
  51. Treede RD, 2015, PAIN, V156, P1003, DOI 10.1097/j.pain.0000000000000160
  52. von Weyhern CH, 2020, LANCET, V395, pE109, DOI 10.1016/S0140-6736(20)31282-4
  53. Waetzig V, 2017, EUR J PHARMACOL, V809, P1, DOI 10.1016/j.ejphar.2017.05.002
  54. World Health Organization, 2021, UPD 3 4 REL COVID 19
  55. Zhang X, 2021, JAMA NETW OPEN, V4, DOI 10.1001/jamanetworkopen.2021.27403

Coleções
Artigos e Materiais de Revistas Científicas - FM/MCM
Artigos e Materiais de Revistas Científicas - COVID-19
Artigos e Materiais de Revistas Científicas - FM/MNE
Artigos e Materiais de Revistas Científicas - FM/MPS
Artigos e Materiais de Revistas Científicas - HC/ICESP
Artigos e Materiais de Revistas Científicas - HC/ICHC
Carregar mais